Determinants of Long-term Survival in Late HIV Presenters: The Prospective PISCIS Cohort Study

Overview

Journal EClinicalMedicine

Specialty General Medicine

Date 2022 Aug 12

PMID 35958520

Authors

Raquel Martin-Iguacel

Juliana Reyes-Uruena

Andreu Bruguera

Jordi Aceiton

Yesika Diaz

Sergio Moreno-Fornes

Pere Domingo

Joaquin Burgos-Cibrian

Juan Manuel Tiraboschi

Isik Somuncu Johansen

Hortensia Alvarez

Josep M Miro

Jordi Casabona

Josep M Llibre

Affiliations

Soon will be listed here.

Abstract

Background: Late HIV diagnosis (i.e CD4≤350 cells/µL) is associated with poorer outcomes. However, determinants of long-term mortality and factors influencing immune recovery within the first years after antiretroviral treatment (ART) initiation are poorly defined.

Methods: From PISCIS cohort, we included all HIV-positive adults, two-year survivors after initiating ART between 2005-2019. The primary outcome was all-cause mortality according to the two-year CD4 count. We used Poisson regression. The secondary outcome was incomplete immune recovery (i.e., two-year CD4<500 cells/µL). We used logistic regression and propensity score matching.

Findings: We included 2,719 participants (16593·1 person-years): 1441 (53%) late presenters (LP) and 1278 non-LP (1145 non-LP with two-year CD4 count >500 cells/µL, reference population). Overall, 113 patients (4·2%) died. Mortality was higher among LP with two-year CD4 count 200-500 cells/µL (aMRR 1·95[95%CI:1·06-3·61]) or <200 cells/µL (aMRR 4·59[2·25-9·37]).Conversely, no differences were observed in participants with two-year CD4 counts >500 cells/µL, regardless of being initially LP or non-LP (aMRR 1·05[0·50-2·21]). Mortality rates within each two-year CD4 strata were not affected by the initial CD4 count at ART initiation (test-interaction, = 0·48). The stronger factor influencing immune recovery was the CD4 count at ART initiation. First-line integrase-inhibitor-(INSTI)-based regimens were associated with reduced mortality compared to other regimens (aMRR 0·54[0·31-0·93]) and reduced risk of incomplete immune recovery in LP (aOR 0·70[0·52-0·95]).

Interpretation: Two-year immune recovery is a good early predictor of long-term mortality in LP after surviving the first high-risk 2 years. Nearly half experienced a favorable immune recovery with a life expectancy similar to non-LP. INSTI-based regimens were associated with higher rates of successful immune recovery and better survival compared to non-INSTI regimens.

Funding: Southern-Denmark University, Danish AIDS-foundation, and Region of Southern Denmark.

Citing Articles

Progress in Early Detection of HIV in Tajikistan.

Alaei K, Kwan B, Torabzadeh H, Akinwalere A, Saydamirovich S, Mohsinzoda G Viruses. 2024; 16(7).

PMID: 39066173 PMC: 11281724. DOI: 10.3390/v16071010.

Has COVID-19 Changed the Incidence and Profile of Late Presenters for HIV Infection in Lodz, Polish Reference Centre, Poland?.

Wojcik-Cichy K, Piekarska A, Jablonowska E J Clin Med. 2024; 13(14).

PMID: 39064161 PMC: 11278052. DOI: 10.3390/jcm13144121.

Risk Factors for Late HIV Presentation in Patients Treated at a Single Belgian Reference Centre from 2018 to 2022.

Scaia D, Fombellida K, Maes N, Moussaoui M, Darcis G Infect Dis Rep. 2024; 16(2):239-248.

PMID: 38525766 PMC: 10961754. DOI: 10.3390/idr16020019.

Efficacy and safety profiles of dolutegravir plus lamivudine vs . bictegravir/emtricitabine/tenofovir alafenamide in therapy-naïve adults with HIV-1.

Wei Y, Li J, Xu R, Wen L, Deng Y, He L Chin Med J (Engl). 2023; 136(22):2677-2685.

PMID: 37914678 PMC: 10684251. DOI: 10.1097/CM9.0000000000002907.

Cardiovascular events in delayed presentation of HIV: the prospective PISCIS cohort study.

Martin-Iguacel R, Vazquez-Friol M, Burgos J, Bruguera A, Reyes-Uruena J, Moreno-Fornes S Front Med (Lausanne). 2023; 10:1182359.

PMID: 37415770 PMC: 10321350. DOI: 10.3389/fmed.2023.1182359.

References

Lapadula G, Chatenoud L, Gori A, Castelli F, Di Giambenedetto S, Fabbiani M . Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μl Despite Effective HAART. PLoS One. 2015; 10(5):e0124741. PMC: 4447446. DOI: 10.1371/journal.pone.0124741. View

Mocroft A, Furrer H, Miro J, Reiss P, Mussini C, Kirk O . The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era. Clin Infect Dis. 2013; 57(7):1038-47. DOI: 10.1093/cid/cit423. View

Guaraldi G, Zona S, Menozzi M, Brothers T, Carli F, Stentarelli C . Late presentation increases risk and costs of non-infectious comorbidities in people with HIV: an Italian cost impact study. AIDS Res Ther. 2017; 14(1):8. PMC: 5311843. DOI: 10.1186/s12981-016-0129-4. View

McManus H, OConnor C, Boyd M, Broom J, Russell D, Watson K . Long-term survival in HIV positive patients with up to 15 Years of antiretroviral therapy. PLoS One. 2012; 7(11):e48839. PMC: 3492258. DOI: 10.1371/journal.pone.0048839. View

Edwards J, Cole S, Hall H, Mathews W, Moore R, Mugavero M . Virologic suppression and CD4+ cell count recovery after initiation of raltegravir or efavirenz-containing HIV treatment regimens. AIDS. 2017; 32(2):261-266. PMC: 5736462. DOI: 10.1097/QAD.0000000000001668. View

May M, Vehreschild J, Obel N, Bonnet F, Mary-Krause M, Samji H . Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study. Clin Infect Dis. 2016; 62(12):1571-1577. PMC: 4885653. DOI: 10.1093/cid/ciw183. View

Samji H, Cescon A, Hogg R, Modur S, Althoff K, Buchacz K . Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013; 8(12):e81355. PMC: 3867319. DOI: 10.1371/journal.pone.0081355. View

Loutfy M, Genebat M, Moore D, Raboud J, Chan K, Antoniou T . A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression. J Acquir Immune Defic Syndr. 2010; 55(4):451-9. DOI: 10.1097/qai.0b013e3181ec28ff. View

Lewden C, Bouteloup V, De Wit S, Sabin C, Mocroft A, Wasmuth J . All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol. 2012; 41(2):433-45. DOI: 10.1093/ije/dyr164. View

10.

Quinn T, Wawer M, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F . Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000; 342(13):921-9. DOI: 10.1056/NEJM200003303421303. View

11.

Edwards J, Cole S, Breger T, Rudolph J, Filiatreau L, Buchacz K . Mortality Among Persons Entering HIV Care Compared With the General U.S. Population : An Observational Study. Ann Intern Med. 2021; 174(9):1197-1206. PMC: 8453103. DOI: 10.7326/M21-0065. View

12.

Serrano-Villar S, Martinez-Sanz J, Ron R, Talavera-Rodriguez A, Fernandez-Felix B, Herrera S . Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study. Lancet HIV. 2020; 7(8):e565-e573. DOI: 10.1016/S2352-3018(20)30202-2. View

13.

Moore D, Harris R, Lima V, Hogg B, May M, Yip B . Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression. J Acquir Immune Defic Syndr. 2009; 52(3):357-63. PMC: 3032437. DOI: 10.1097/QAI.0b013e3181b62933. View

14.

Neesgaard B, Mocroft A, Zangerle R, Wit F, Lampe F, Gunthard H . Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium. PLoS One. 2020; 15(12):e0243625. PMC: 7774984. DOI: 10.1371/journal.pone.0243625. View

15.

Mocroft A, Lundgren J, Sabin M, Monforte A, Brockmeyer N, Casabona J . Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med. 2013; 10(9):e1001510. PMC: 3796947. DOI: 10.1371/journal.pmed.1001510. View

16.

Dias Lima V, Eyawo O, Ma H, Lourenco L, Chau W, Hogg R . The impact of scaling-up combination antiretroviral therapy on patterns of mortality among HIV-positive persons in British Columbia, Canada. J Int AIDS Soc. 2015; 18:20261. PMC: 4598331. DOI: 10.7448/IAS.18.1.20261. View

17.

Rava M, Dominguez-Dominguez L, Bisbal O, Lopez-Cortes L, Busca C, Antela A . Late presentation for HIV remains a major health issue in Spain: Results from a multicenter cohort study, 2004-2018. PLoS One. 2021; 16(4):e0249864. PMC: 8059864. DOI: 10.1371/journal.pone.0249864. View

18.

Montaner J, Lima V, Barrios R, Yip B, Wood E, Kerr T . Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010; 376(9740):532-9. PMC: 2996043. DOI: 10.1016/S0140-6736(10)60936-1. View

19.

Lundgren J, Babiker A, Gordin F, Emery S, Grund B, Sharma S . Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015; 373(9):795-807. PMC: 4569751. DOI: 10.1056/NEJMoa1506816. View

20.

Walmsley S, Baumgarten A, Berenguer J, Felizarta F, Florence E, Khuong-Josses M . Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial. J Acquir Immune Defic Syndr. 2015; 70(5):515-9. PMC: 4645960. DOI: 10.1097/QAI.0000000000000790. View